← Leaderboards
Heike Wulff
University Of California Davis
$18,064,160
Attributed
$21,326,421
Total exposure
20
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.7M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$21,326,421 · 20
By mechanism
U54$8,528,462 · 5
R01$5,962,468 · 4
R21$3,298,207 · 8
R61$1,587,047 · 1
UG3$1,557,737 · 1
R56$392,500 · 1
Top collaborators
- Arthi Kanthasamy4 shared
- Lee-Way Jin2 shared
- Leonard K Kaczmarek2 shared
- Pamela J Lein2 shared
- Vladimir M. Yarov-Yarovoy2 shared
- Miao Zhang1 shared
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsBrainDesignAcuteDrug KineticsBaseNeuronsIn VivoNovel TherapeuticsCellsPharmaceutical ChemistryInhibitor/AntagonistPreventDoseSeizuresAnticonvulsantsPlayMediatingAffectLeadSmall MoleculeIntoxicationPharmacologyPenetration
Grant awards (58)
Molecular mechanism for pharmacological activation of KCa2 channels$580,619
R01 · FY2025 · NS
The Role of KCa3.1 in Microglial function and in Parkinsons disease pathogenesis$382,212
R01 · FY2025 · NS
Core A: Analytical and Medicinal Chemistry Core$345,337
U54 · FY2025 · NS · contact PI
Core A: Analytical and Medicinal Chemistry Core$273,700
U54 · FY2024 · NS · contact PI
The Role of KCa3.1 in Microglial function and in Parkinsons disease pathogenesis$383,147
R01 · FY2023 · NS
Core A: Analytical and Medicinal Chemistry Core$272,000
U54 · FY2023 · NS · contact PI
Development of therapeutic antibodies to target sodium channels involved in pain signaling$1,587,047
R61 · FY2022 · NS
KCa2 Channel Activators for Opioid Use Disorder$419,881
R21 · FY2022 · DA · contact PI
The Role of KCa3.1 in Microglial function and in Parkinsons disease pathogenesis$384,050
R01 · FY2022 · NS
Core A: Analytical and Medicinal Chemistry Core$271,150
U54 · FY2022 · NS · contact PI
Probe and Pharmaceutical Optimization Core (PPOC)$616,408
U54 · FY2021 · NS · contact PI
The Role of KCa3.1 in Microglial function and in Parkinsons disease pathogenesis$398,173
R01 · FY2021 · NS
Probe and Pharmaceutical Optimization Core (PPOC)$617,268
U54 · FY2020 · NS · contact PI
Microglial K+ Channels in Ischemic Stroke$334,406
R01 · FY2020 · NS · contact PI
Identifying Molecular Targets for the Proconvulsant Activity of TETS$186,958
R21 · FY2020 · NS
Optimization of non-addictive biologics to target sodium channels involved in pain signaling$1,557,737
UG3 · FY2019 · NS
Probe and Pharmaceutical Optimization Core (PPOC)$617,171
U54 · FY2019 · NS · contact PI
Microglial K+ Channels in Ischemic Stroke$334,406
R01 · FY2019 · NS · contact PI
Identifying Molecular Targets for the Proconvulsant Activity of TETS$227,053
R21 · FY2019 · NS
Probe and Pharmaceutical Optimization Core (PPOC)$615,720
U54 · FY2018 · NS · contact PI
Microglial K+ Channels in Ischemic Stroke$334,406
R01 · FY2018 · NS · contact PI
Structure Assisted Design of SK Channel Selective Activators$185,517
R21 · FY2018 · NS · contact PI
Probe and Pharmaceutical Optimization Core (PPOC)$619,981
U54 · FY2017 · NS · contact PI
Microglial K+ Channels in Ischemic Stroke$334,406
R01 · FY2017 · NS · contact PI
Structure Assisted Design of SK Channel Selective Activators$224,767
R21 · FY2017 · NS · contact PI
Probe and pharmaceutical optimization core$418,620
U54 · FY2016 · NS · contact PI
Analytical chemistry$402,708
U54 · FY2016 · NS · contact PI
Microglial Potassium Channels in Ischemic Stroke$392,500
R56 · FY2016 · NS · contact PI
Probe and pharmaceutical optimization core$417,130
U54 · FY2015 · NS · contact PI
Analytical chemistry$402,708
U54 · FY2015 · NS · contact PI
Probe and pharmaceutical optimization core$415,777
U54 · FY2014 · NS · contact PI
Analytical chemistry$402,708
U54 · FY2014 · NS · contact PI
The microglial potassium channels Kv1.3 and KCa3.1 as therapeutic targets for neu$311,297
R01 · FY2014 · GM · contact PI
Probe and pharmaceutical optimization core$9,641
U54 · FY2014 · NS · contact PI
Analytical chemistry$9,641
U54 · FY2014 · NS · contact PI
Analytical chemistry$570,108
U54 · FY2013 · NS · contact PI
Probe and pharmaceutical optimization core$414,546
U54 · FY2013 · NS · contact PI
The microglial potassium channels Kv1.3 and KCa3.1 as therapeutic targets for neu$300,402
R01 · FY2013 · GM · contact PI
Probe and pharmaceutical optimization core$413,430
U54 · FY2012 · NS · contact PI
Analytical chemistry$402,710
U54 · FY2012 · NS · contact PI
The microglial potassium channels Kv1.3 and KCa3.1 as therapeutic targets for neu$311,297
R01 · FY2012 · GM · contact PI
Design of Slack Channel Activators$239,179
R21 · FY2012 · NS
Optimization of KCa2 Channel Activators as Neuroscience Tools and Potential Drugs$220,262
R21 · FY2012 · NS · contact PI
The Microglial Kv1.3 Channel in Alzheimer's Disease$156,145
R21 · FY2012 · AG
The microglial potassium channels Kv1.3 and KCa3.1 as therapeutic targets for neu$301,119
R01 · FY2011 · GM · contact PI
Design of Slack Channel Activators$255,087
R21 · FY2011 · NS
Optimization of KCa2 Channel Activators as Neuroscience Tools and Potential Drugs$219,611
R21 · FY2011 · NS · contact PI
The Microglial Kv1.3 Channel in Alzheimer's Disease$187,116
R21 · FY2011 · AG
Alkoxypsoralens, Small Molecule Blockers of the Voltage-Gated Kv1.3 Channel$255,640
R01 · FY2009 · GM · contact PI
Alkoxypsoralens, Small Molecule Blockers of the Voltage-Gated Kv1.3 Channel$243,176
R01 · FY2009 · GM · contact PI
Alkoxypsoralens, Small Molecule Blockers of the Voltage-Gated Kv1.3 Channel$255,640
R01 · FY2008 · GM · contact PI
Alkoxypsoralens, Small Molecule Blockers of the Voltage-Gated Kv1.3 Channel$255,640
R01 · FY2007 · GM · contact PI
Small Molecule Kv1.3 Blockers as New Therapeutics for Multiple Sclerosis$165,769
R21 · FY2007 · NS · contact PI
SK Channel Openers as Therapeutics for Cerebellar Ataxia$39,000
R21 · FY2007 · NS · contact PI
Alkoxypsoralens, Small Molecule Blockers of the Voltage-Gated Kv1.3 Channel$262,432
R01 · FY2006 · GM · contact PI
SK Channel Openers as Therapeutics for Cerebellar Ataxia$211,298
R21 · FY2006 · NS · contact PI
Small Molecule Kv1.3 Blockers as New Therapeutics for Multiple Sclerosis$170,438
R21 · FY2006 · NS · contact PI
SK Channel Openers as Therapeutics for Cerebellar Ataxia$190,126
R21 · FY2005 · NS